AY20 Stock Overview
A pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Aytu BioPharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.28 |
| 52 Week High | US$20.00 |
| 52 Week Low | US$2.89 |
| Beta | -0.41 |
| 11 Month Change | 0% |
| 3 Month Change | 1,504.21% |
| 1 Year Change | -81.83% |
| 33 Year Change | -98.71% |
| 5 Year Change | n/a |
| Change since IPO | -99.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| AY20 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -7.0% | -0.4% |
| 1Y | -81.8% | -21.6% | 7.1% |
Return vs Industry: AY20 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: AY20 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| AY20 volatility | |
|---|---|
| AY20 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AY20's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine AY20's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 164 | Josh Disbrow | aytubio.com |
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency.
Aytu BioPharma, Inc. Fundamentals Summary
| AY20 fundamental statistics | |
|---|---|
| Market cap | €7.66m |
| Earnings (TTM) | -€71.67m |
| Revenue (TTM) | €96.81m |
0.1x
P/S Ratio-0.1x
P/E RatioIs AY20 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AY20 income statement (TTM) | |
|---|---|
| Revenue | US$105.58m |
| Cost of Revenue | US$42.73m |
| Gross Profit | US$62.85m |
| Other Expenses | US$141.02m |
| Earnings | -US$78.17m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -20.69 |
| Gross Margin | 59.53% |
| Net Profit Margin | -74.04% |
| Debt/Equity Ratio | 47.8% |
How did AY20 perform over the long term?
See historical performance and comparison